Departamento de Bioquímica Clínica, Área Hematología, Hospital de Clínicas "José de San Martín", Universidad de Buenos Aires, Av. Córdoba 2351, C1120AAF Buenos Aires, Argentina.
Departamento de Bioquímica Clínica, Facultad de Farmacia y Bioquímica, Instituto de Fisiopatología y Bioquímica Clínica (INFIBIOC), Universidad de Buenos Aires, Córdoba 2351, C1120AAF Buenos Aires, Argentina.
Curr Med Chem. 2023;30(35):3993-4031. doi: 10.2174/0929867329666221003101548.
Alzheimer's disease (AD) is a progressive neurodegenerative disease characterized by marked cognitive decline, memory loss, and spatio-temporal troubles and, in severe cases, lack of recognition of family members. Neurological symptoms, cognitive disturbances, and the inflammatory frame due to COVID-19, together with long-term effects, have fueled renewed interest in AD based on similar damage. COVID-19 also caused the acceleration of AD symptom onset. In this regard, the morbidity and mortality of COVID-19 were reported to be increased in patients with AD due to multiple pathological changes such as excessive expression of the viral receptor angiotensin-converting enzyme 2 (ACE2), comorbidities such as diabetes, hypertension, or drug-drug interactions in patients receiving polypharmacy and the high presence of proinflammatory molecules. Furthermore, the release of cytokines, neuroinflammation, oxidative stress, and ferroptosis in both diseases showed common underlying mechanisms, which together worsen the clinical picture and prognosis of these patients.
阿尔茨海默病(AD)是一种进行性神经退行性疾病,其特征是明显的认知能力下降、记忆力丧失、时空障碍,在严重的情况下,还会不认识家人。COVID-19 引起的神经症状、认知障碍和炎症框架,加上长期影响,基于类似的损伤,重新引起了对 AD 的兴趣。COVID-19 还导致 AD 症状发作的加速。在这方面,由于 COVID-19 患者中过度表达病毒受体血管紧张素转换酶 2 (ACE2)等多种病理变化、合并症(如糖尿病、高血压或接受多药治疗的患者的药物相互作用)以及促炎分子的高存在,导致 AD 患者的发病率和死亡率增加。此外,这两种疾病中的细胞因子释放、神经炎症、氧化应激和铁死亡显示出共同的潜在机制,这些机制共同使这些患者的临床情况和预后恶化。